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Multiple sclerosis (MS) disease risk is associated with reduced sun-
exposure. This study assessed the relationship between measures
of sun exposure (vitamin D [vitD], latitude) and MS severity in the
setting of two multicenter cohort studies (nNationMS = 946, nBIONAT =
990). Additionally, effect-modification bymedication and photosensitivity-
associated MC1R variants was assessed. High serum vitD was associated
with a reduced MS severity score (MSSS), reduced risk for relapses, and
lower disability accumulation over time. Low latitudewas associatedwith
higher vitD, lower MSSS, fewer gadolinium-enhancing lesions, and lower
disability accumulation. The association of latitude with disability was
lacking in IFN-β–treated patients. In carriers of MC1R:rs1805008(T), who
reported increased sensitivity toward sunlight, lower latitude was associ-
atedwith higher MRI activity, whereas for noncarriers there was less MRI
activity at lower latitudes. In a further exploratory approach, the effect of
ultraviolet (UV)-phototherapy on the transcriptome of immune cells of
MS patients was assessed using samples from an earlier study. Photo-
therapy induced a vitD and type I IFN signature that was most apparent
inmonocytes but that could also be detected in B and T cells. In summary,
our study suggests beneficial effects of sun exposure on established MS,
as demonstrated by a correlative network between the three factors:
Latitude, vitD, and disease severity. However, sun exposure might be
detrimental for photosensitive patients. Furthermore, a direct induction
of type I IFNs through sun exposure could be another mechanism of UV-
mediated immune-modulation in MS.
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Multiple sclerosis (MS), characterized by demyelinating le-sions, is the most common neuroinflammatory disease of
the central nervous system and presumably of autoimmune ori-
gin (1). In most cases, the disease is diagnosed at a young age,
predominantly occurs in women, and follows a relapsing-
remitting course, which can be superseded by a secondary, pro-
gressive stage (2). Etiologically, environmental factors have been
shown to play an important role (3) and insufficient sunlight
exposure has been suspected to be critical for the initial devel-
opment of MS (4). The best characterized mediator of ultraviolet
radiation (UVR)-dependent effects is vitamin D (vitD), which is
generated from its precursor 7-dehydrocholesterole (7-DHC) in
the skin, further metabolized in the liver and kidney, and that
exerts its function in its active form 1-α,25-dihydroxyvitamin D3
[1α,25(OH)2D3], also known as calcitriol (5). Precursors of active
vitD can also be found in food in the form of ergocalciferol (or
vitamin D2), which is, however, of little relevance for total serum
vitD levels (6). For MS, low vitD levels have been shown to be
associated with disease risk (7, 8) and Mendelian randomization
studies hint toward a causal role for vitD (9, 10). However, it is
possible that alternative UVR-dependent pathways play a role as
well (11). A study by Langer-Gould et al. (12) suggested that
serum vitD is only a risk factor for MS in Whites, but not in
people of color, although lifetime UVR-exposure was associated
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there is still an ongoing debate, whether sunlight and vitD also
modulate disease severity and worsening. Observational
studies suggested vitD-dependent effects, but prospective
supplementation studies have so far been inconclusive and
reverse causality cannot be excluded as a source of bias. By
using the sun-exposure measures vitD and latitude, we show
correlations between vitD/latitude, vitD/disease severity, and
latitude/disease severity in two multicentric cohorts. Although
vitD cannot be proven as the causal factor, we provide evi-
dence for clinically relevant effects of sunlight exposure. Fur-
thermore, this study suggests sunlight-triggered pathways
other than vitD could play additional and modulatory roles,
as well.
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with reduced risk in both, arguing against vitD as the mediator of
UVR-effects. Hedström et al. (13) report from a large population-
based study that besides vitD-dependent effects, vitD-independent
effects of UVR also play a role. Results from the PhoCIS (Photo-
therapy for Clinically Isolated Syndrome [CIS]) trial and its post hoc
analysis suggest effects of UVR even in patients with a serum vitD
status of ≥80 ng/mL (14, 15). Furthermore, it is still a topic of debate
whether UVR/vitD only modulate disease risk, or if disease severity
of established MS is affected, as well. In mouse models, UVR was
shown to ameliorate disease, but this was independent of vitD and its
receptor (16–19). Human observational studies suggested an influ-
ence of vitD on disease activity (20, 21) and prospective trials also
suggested an effect on the formation of lesions, but the primary
endpoints of supplementation studies have not been met so far,
raising doubt about the role of vitD in ongoing disease (22–24). It has
also been argued that reverse causation could influence the results
from observational studies (i.e., low vitamin D could be caused by
disease activity rather than vice versa) (4).
Reports on the effect of latitude (which can be regarded as an
independent measure of sun-exposure) on disease severity are
scarce and could either not identify any effects or showed con-
tradictory effects (25, 26). Noteworthy, besides the assumed
main effects of UVR and vitD on MS severity, there might be
factors that could alter the effects of UVR/vitD. Medication—
especially IFN-β therapy—has been suggested to modulate vitD-
production [potentially by decreasing serum cholesterol (27)]
and its treatment effect. Ambiguous results have been reported
regarding the effect of vitD in IFN-β–treated patients: Two
studies reported positive interactions between vitD and IFN-β
(28, 29). Another study found the association between vitD and
disease activity to disappear after IFN-β treatment onset, while
in the BENEFIT and BEYOND trials the effect of vitD was
apparent despite IFN-β treatment (20, 30, 31). Besides medica-
tion, genetic factors that determine pigmentation and photo-
sensitivity could play an important role in modulating UVR
effects. One genetic factor known to alter an individual’s re-
sponse to UVR is the melanocortin 1 receptor (MC1R) geno-
type. The MC1R is responsible for melanin synthesis upon UVR
exposure and carrying loss-of-function variants results in a red
hair and fair skin phenotype with increased photosensitivity (32,
33). The MC1R is also known to confer immunosuppressive
effects and functional signaling ameliorates disease course in
mouse models of MS (34). Moreover, the MC1R agonist adre-
nocorticotropic hormone (ACTH) is used to treat disease exac-
erbations in MS and part of the effect of ACTH is assumed to be
mediated through the MC1R (35). Therefore, the MC1R could
be a mediator or modifier of UVR-effects in MS.
This study aims to provide a better understanding of the effects
of UVR and vitD on MS severity, and to deduce the role of
modulatory factors like medication and photosensitivity-
associated genotypes. In the setting of two large, independent
multicenter studies, the effects of the sun-exposure measures vitD
and latitude on disease severity were investigated. To assess the
role of further mechanistic pathways in mediating or modifying
UVR and vitD effects, interactions between sun-exposure mea-
sures and either medication or theMC1R genotype were assessed.
Finally, in an unbiased exploratory approach the UVB-induced
transcriptomic changes in immune cells of MS patients from our
2014 pilot study were assessed (18), illuminating the pathways
triggered by UVR in peripheral immune cells of MS patients.
Results
Cohort Characteristics. For the NationMS cohort, data of
946 treatment-naïve patients at baseline with CIS or relapsing-
remitting multiple sclerosis (RRMS) were acquired (disease du-
ration <2 y). The study procedure is shown in Fig. 1. Baseline
characteristics are described in SI Appendix, Table S1. Genotyping
for MC1R was successful and passed quality control (QC) for 883
(97.25%) of the 908 patients that had full demographic and
clinical information available. The most common MC1R variant
allele was rs1805008:T (n = 148 of 883, 16.76% with ≥1 risk allele,
minor allele frequency [MAF] = 8.60%), followed by rs2228479:A
(n = 140 of 883, 15.86% with ≥1 risk allele, MAF = 8.10%), and
rs885479:A (n = 76 of 883, 8.61% with ≥1 risk allele, MAF =
4.42%). Patients were subjected to regular follow-ups. In total, for
798 patients, longitudinal data were available (Fig. 1). Of these,
148 (18.55%) patients remained untreated after baseline assess-
ment, while 650 (81.46%) received treatment. The most pre-
scribed medication was IFN-β (n = 364, 45.61% of all patients,
including untreated) (SI Appendix, Table S2). A change in medi-
cation was recorded for 233 patients (29.20% ever changed).
Moreover, 355 patients (44.49%) reported a relapse in the time
after baseline assessment with a median time to relapse of 245 d
(interquartile range = 102.0–470.5). For another 671 patients,
disability was assessed 2 y after baseline, and the median change in
expanded disability status scale (EDSS) was 0 (interquartile
range = −0.5–0.5), with 233 patients (34.72%) who presented with
an increase after those 2 y, 220 (32.79%) patients with a decrease,
and 218 (32.49%) whose EDSS remained unchanged.
For the BIONAT cohort, data of 990 MS patients at their
baseline assessment were acquired (Fig. 1). Full information on
demographics, clinical subtype, medication, and the multiple
sclerosis severity score (MSSS) were available for 808 patients
(81.62%). Most patients had already received therapy before the
baseline assessment. The most prescribed medication was IFN-β
(59.77%) (SI Appendix, Table S2).
The characteristics of the five patients treated with UVB-
phototherapy were previously published (18). Two of the pa-
tients were treated with IFN-β, one with Glatirameracetate
(GA), one with Natalizumab, and one had not received any
treatment. All patients with available biomaterial were included
for this study and there were no specific selection criteria besides
those already published in Breuer et al. (18).
Latitude and Prior Medication Determine Serum vitD Levels. With
decreasing latitude, the amount of UVR reaching the earth’s
surface increases; thus, latitude can be regarded as a measure of
sun exposure. Indeed, a north–south gradient of UVR can be
observed along the latitude axis in both Germany and France,
with an increase in average yearly UVR of about twofold from
the north of Germany to the south of France, as measured by
NASA satellite data (Fig. 2A). To demonstrate that lower latitude
also correlates with higher actual UVR exposure on a population
level, the correlation between latitude and serum vitD levels was
tested in both cohorts. As expected, lower latitude was associated
with higher vitD levels (β = −0.56, 95% confidence interval [CI] =
[−1.030 to −0.090], P = 0.020) in the NationMS cohort. Consistent
with the results from the NationMS cohort, in the BIONAT cohort
lower latitude was also associated with higher vitD levels (β =
−0.44, 95% CI = [−0.87 to −0.018], P = 0.041) (SI Appendix, Fig.
S1 A and B). However, not all patients from the BIONAT cohort
were untreated and IFN-β treatment has been shown to modulate
vitD levels, potentially by decreasing serum cholesterol, which in
turn modulates the amount of the vitD-precursor 7-DHC (27, 29).
In a subgroup analysis of patients who had received IFN-β therapy,
there seemed to be no effect of latitude on vitD levels, while un-
treated and GA-treated patients showed the expected increase of
vitD as latitude decreases (SI Appendix, Fig. S1C). In line with
previous reports, IFN-β–treated patients also had higher vitD levels
than therapy-naïve patients (β = 4.020, 95% CI = [0.450–7.560],
P = 0.031) (SI Appendix, Fig. S1D) (29).
Low vitD Levels and High Latitude Are Associated with Clinical
Disease Severity. Based on the available evidence before the
start of the study, the association between latitude, vitD, and
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clinical severity was assessed (Fig. 2). In the NationMS cohort
vitD levels were associated with lower disability, as assessed by
the MSSS (β = −0.014, 95% CI = [−0.026 to −0.002], P = 0.021).
Higher latitude (corresponding to lower sun exposure) was as-
sociated with worse MSSS scores in the NationMS cohort (β =
0.092, 95% CI = [−0.016–0.168], P = 0.018) (Fig. 2B). A similar
result was obtained when substituting latitude by satellite-
derived UVR estimates (SI Appendix, Table S3). The risk for
gadolinium (Gd)-enhancing lesions increased by 8.31% for every
1° increase in latitude (risk ratio [RR] = 1.08, 95% CI =
[1.01–1.16], P = 0.030) (Fig. 2C).
The Association of Latitude with Disability Is Absent in Patients Treated
with IFN-β. The hypotheses were then also tested in the BIONAT
cohort. Here, higher vitD levels showed an association with lower
disability as well (β = −0.022, 95% CI = [−0.037 to −0.007], P =
0.007) (Fig. 2D). However, in contrast to the results from the
NationMS cohort, there was no clear trend for an effect of latitude on
the MSSS (β = −0.004, 95% CI = [−0.076–0.068], P = 0.913). As not
all BIONAT patients were therapy-naïve at baseline and IFN-β
therapy has been shown to modulate vitD synthesis, but also to
eradicate the association between vitD and severity measures, it was
hypothesized that the missing effect of latitude could also be due to
confounding by IFN-β therapy (28–30). Interaction analyses indeed
showed that the effect of latitude on disability was significantly dif-
ferent depending on IFN-β treatment status (β = 0.145, 95% CI
[0.005–0.283], interaction-P = 0.042). Subsequent subgroup analyses
confirmed that higher latitude was associated with a worse MSSS in
patients, whose last medication was not IFN-β (β = 0.115, 95% CI =
[0.001–0.227], P = 0.047), while patients treated with IFN-β did not
show this effect (β = −0.048, 95% CI = [−0.141–0.045], P = 0.310)
(Fig. 2E).
High vitD and Low Latitude Are Associated with Reduced Risk for
Relapses and Disability Accumulation. To further test the predic-
tive capacity of vitD and latitude with regard to accumulation of
disease burden, data on confirmed relapses after baseline in the
NationMS cohort were assessed (Fig. 3). In a mixed-effects Cox
regression vitD (for statistical inference treated as continuous
variable) reduced the risk for a relapse by 1% for every 1 ng/mL
of serum vitD at baseline (hazard ratio [HR] = 0.988, 95% CI =
[0.978–0.999], P = 0.028). For the purpose of visualization, vitD
was grouped into three categories: 1) The 20% of patients with
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Fig. 1. Study flow chart. Data of 946 therapy-naïve patients were acquired for the NationMS cohort and data of 990 BIONAT patients with a history of
previous medication for MS have been acquired. Datasets were filtered for missing information with 908 NationMS and 808 BIONAT patients remaining at
baseline. For the analysis of disease severity, BIONAT patients were further excluded when information on site of first event was unknown/unavailable
(remaining total n = 611, n for remaining patients with available information on serum vitD = 451). To assess the influence of sun-exposure measures on
serum vitD levels, this information was not necessary and n = 594 patients were assessed. For NationMS, longitudinal information on relapses was available
for n = 798 and information on disability 2 y after baseline was available for 671 patients.
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with the lowest vitD levels (<10.86 ng/mL); and 3) the patients in
between (Fig. 3A). This categorization is also close to common
definitions of optimal (≥30 ng/mL) and deficient (<10 ng/mL)
vitD levels (36, 37). As categorization exclusively served the
purpose of visualization, results from statistical models were not
influenced by this and relied on continuous scale serum vitD.
Furthermore, baseline vitD was associated with a lower grade of
disability accumulation, as measured by the ΔEDSS (β = −0.006,
95% CI = [−0.012 to −0.0003], P = 0.046) (Fig. 3B). Latitude
showed no significant effect on the risk for relapses (Fig. 3C).
However, in line with the results from the baseline analysis,
lower latitude was associated with significantly lower ΔEDSS
(β = 0.67, 95% CI = [0.026–0.106], P = 0.001) (Fig. 3D).
Photosensitivity-Associated MC1R Missense Variants Might Modify
UVR-Mediated Effects. MC1R missense variants strongly increase
an individual’s sensitivity to UVR and could, therefore, modify
the beneficial effect of UVR on MS disease severity. First, the
previously described influence of MC1R genotype on photosen-
sitivity was confirmed using ordinal regression (Fig. 4 A–C).
Whereas there was no statistically significant effect for the low-
penetrance variants rs885479 (odds ratio [OR] = 2.05, 95% CI =
[0.764–5.541], P = 0.153) and rs2228479 (OR = 0.97, 95% CI =
[0.492–1.911], P = 0.936), the T allele of the high-penetrance
variant rs1805008 increased the odds for a severe reaction to
sunlight by 91.5% (OR = 1.92, 95% CI = [1.040–3.560], P =
0.038) (Fig. 4A). Biological sex did not modify the effect of
rs1805008 on photosensitivity (interaction-P = 0.308). Next, as
rs1805008:T carriers reported severe reactions to sunlight, the
effect of an interaction term between measures of sun exposure
(latitude, vitD) and rs1805008 on clinical severity was assessed
(at baseline). No significant interactions were found regarding
the MSSS (Fig. 4D). The interaction term of rs1805008:T and
latitude was nominally significant in the analysis of Gd-
enhancing lesions (interaction-P = 0.001). In subgroup analyses
for carriers of rs1805008:T, the risk for Gd-enhancing lesions
increased by 20.5% for every 1° decrease in latitude (RR = 1.21,
95% CI = [1.010–1.437], P = 0.034), while it was reduced by
11.6% in noncarriers for every 1° decrease in latitude (RR =
0.88, 95% CI = [0.808–0.947], P = 9.2 × 10−4) (Fig. 4E). Both
subgroup analyses were nominally significant. Furthermore, the
statistical significance of the interaction between rs1805008 and
latitude held in subgroup analyses stratified by biological sex
(Pmale = 0.036, Pfemale = 0.018). Inconsistencies between read-
outs (MSSS and Gd-enhancing lesions) might be due to the
known weak correlation between Gd-enhancing lesions and the
MSSS (ρ = 0.03, P = 0.33). No interaction between rs1805008:T
and vitD levels regarding Gd-enhancing lesions was found (RR =
1.00, 95% CI = [0.968–1.137], P = 0.825).
The vitD and the Type I IFN Pathway Are Up-Regulated upon UVB
Phototherapy in MS Patients. As it is unclear which molecular
pathways mediate the beneficial effects of UVR in MS, periph-
eral blood mononuclear cells (PBMC) samples of five UVB-
treated MS patients from our 2014 pilot study (18) were FAC-
sorted for CD4 T cells, CD8 T cells, monocytes, B cells, and
subjected to RNA-sequencing (RNA-seq) analysis (Fig. 5A). For
CD4 T cells there were 268 genes that were regulated with P <
0.05, 524 genes for CD8 T cells, 411 genes for monocytes, and
407 genes for B cells (Datasets S1–S4). Among these were pre-
viously described markers of vitD signaling: For example, VDR
(CD4 T cells), NR4A2, NR4A3 (CD4, CD8 T cells, and mono-
cytes), and CD14 (monocytes) (Fig. 5 B–E). Furthermore, a first
visual inspection suggested an enrichment of genes belonging to
the type I IFN-family—including IFITM1, IFITM2, IFITM3,
MX1, IRF8, IRF7, IFI44L, IFIT2, and IFIT3—and this was most
apparent in monocytes (Fig. 5 B–E). Regulation of exemplary
genes for both pathways are plotted in Fig. 5 F–I. A down-
regulation of the Aryl-hydrocarbon receptor-associated genes
AHR and TIPARP was observed as well. Next, to check whether
the vitD and the type I IFN pathway were significantly enriched,
permutation tests using reference gene sets from wikipathways
were performed. A significant enrichment of vitD-associated
genes was found in CD8 T cells (gene ratio [GR] = 0.108, P =
0.002), monocytes (GR = 0.079, P = 0.018), and B cells (GR =
0.114, P = 1 × 10−4) (Dataset S5). Furthermore, type I IFN
pathway-associated genes were significantly enriched in CD8
T cells (GR = 0.101, P = 0.018), monocytes (GR = 0.156, P = 1 ×
10−6), and B cells (GR = 0.083, P = 0.027) (Fig. 5 J–M and
Dataset S6).
Discussion
High latitude has been identified as a major risk factor for the
development of MS (4). This association is suspected to be
mediated by low exposure to UVR and subsequent low vitD
levels. Although this is a worldwide phenomenon, there are ex-
ceptions to the rule. An unexpectedly high MS prevalence has
been described for the island of Sardinia, despite high exposure
to beneficial environmental factors like UVR, but also a
seafood-rich diet. This exemplifies the importance of the genetic
background, especially in historically rather isolated populations.
Even though environmental factors are assumed to contribute
more to overall MS risk than genetics, certain genetic composi-
tions seem to be able to invert this balance (3, 38). Notably,
populations like the Maori, Amerindian, and Inuit have been
described to have a low MS risk, despite living in high-risk areas,
which is of relevance for this study as in these populations
hyporesponsive MC1R variants are rare (39).
Besides the risk to develop MS, it is still a topic of debate
whether UVR, vitD, or other UVR-dependent pathways, have
an influence on disease severity and worsening over time, as well.
Most work has focused on vitD and only few studies investigated
alternative UVR-mediated pathways, although several candidate
molecules have been proposed to mediate UVR-effects (e.g.,
nitric oxide, cis-urocanic acid, and tryptophan metabolites) (11,
40, 41). In the present study, data of two large, independent
multicenter cohorts was used to test the association between
latitude and vitD with MS disease severity. In this regard,
modification of UVR-dependent effects by medication and
photosensitivity-associated MC1R missense alleles was investi-
gated as well. To explore by which mechanisms UVR could exert
immunomodulation in MS, next-generation sequencing was
performed to assess the UVB phototherapy-induced changes in
immune cells in a small group of patients.
In line with previous studies, we observed lower disease se-
verity and a lower tendency toward disease worsening in patients
with higher vitD levels in the NationMS cohort (4). Cutoffs for
immunomodulation by vitD have been discussed previously in
the post hoc analyses of the BENEFIT trial, suggesting ≥50
nmol/mL (equal to 20 ng/mL) to sensibly discriminate patients
with low or high risk for disease activity and progression (20).
Furthermore, results from BEYOND indicate that for optimal
immunomodulation an even higher serum vitD status (≥100
nmol/mL) might be necessary (31). In line with these observa-
tions, our study indicates a linear relationship with no natural
cutoff. Furthermore, confounding of our results by genetic pre-
disposition is unlikely, as two large studies showed no interaction
between the effects of UVR-/vitD and HLA-DRB1*15:01, a
major genetic risk factor for MS (31, 42).
Expectedly, vitD levels were also strongly associated with lat-
itude. Therefore, latitude itself is a sound proxy for sun exposure on a
population level, especially if adjusted for the sampling month as well.
Consistently, latitude also showed a significant association with dis-
ease severity and worsening in the NationMS cohort. Confirming this,
substituting a center’s latitude by satellite-derived UVR-estimates and
4 of 12 | PNAS Ostkamp et al.
https://doi.org/10.1073/pnas.2018457118 Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
rerunning the analyses revealed similar associations. Although this
cannot directly prove a causal effect of vitD, the intercorrelative
network between latitude, vitD (two measures of sun exposure on
conceptually different levels), and disability is strongly suggestive of
positive effects of UVR in established MS. In the BIONAT cohort
vitD was also associated with reduced disability. Interestingly, the
effect of latitude was only observed in patients who were not treated
with IFN-β before. Since interactions between IFN-β treatment and
vitD have been shown before and it is known that IFN-β modulates
vitD synthesis (28–30), it is possible that the normal association be-
tween latitude and vitD is altered by IFN-β treatment, which is also in
line with the observation that patients with IFN-β therapy had sig-
nificantly higher vitD levels compared to treatment-naïve patients,
and vitD levels seemed not to be different across northern and
southern latitudes for IFN-β–treated patients. However, previous
studies analyzing the interaction between UVR/vitD and IFN-β have
provided ambiguous results; for example, Løken-Amsrud et al. (30)
report that after initiation of IFN-β the association between disease
activity and vitD was lost, whereas data from Ascherio et al. (20)
suggest that even in IFN-β–treated patients the effect of vitD persists.
Although the reasons for this discrepancy cannot be fully explained by
our data, it supports the previous notion that there is a strong rela-
tionship between vitD and IFN-β signaling.
To uncover the UVR-induced transcriptomic changes in im-
mune cells in MS patients, the effect of UVB phototherapy was
assessed using next-generation sequencing. Due to the explor-
atory nature of this approach, the limited sample size and the
high false-discovery rate burden, genes with P < 0.05 were
regarded as regulated. The regulation of genes such as NR4A2,
NR4A3, CD14, and the gene for the vitD receptor (VDR), which
have been reported multiple times to indicate a vitD response
(43, 44), underpins the integrity of the approach and is in line
with the profound vitD increase upon phototherapy that was
previously demonstrated in these patients (18). The up-
regulation of VDR can be interpreted as an intrinsic sensitivity
analysis and demonstrates that despite the limited number of
samples, biologically meaningful results could be obtained. As
vitD counteracts parathyroid hormone (PTH) expression (45), it
is likely that the down-regulation of the NR4A family is due to a
reduction of PTH, as PTH has been shown to increase NR4A
expression (46). This is also in line with the observed general
enrichment of vitD-associated genes in permutation tests.
Moreover, we identified regulation of the type I IFN pathway
by phototherapy. As an up-regulation of type I IFN-associated
genes was observed in all donors of whom only two received
IFN-β therapy, this relationship cannot be explained by IFN-β
therapy, but instead is likely to be a direct result of phototherapy.
Type I IFN induction was most apparent in monocytes, the natural
producers of type I IFNs in the context of pathogen control (47). A
UVR-dependent induction of type I IFNs could provide an alterna-
tive explanation why the effect of latitude on disability was absent in
IFN-β–treated patients. If part of the effect of UVR is mediated
directly through type I IFNs, it is possible that IFN-β treatment could
mask the effects of UVR/latitude. Of note, there is no known asso-
ciation between latitude and prevalence of neuromyelitis optica, an
MS-related disease that worsens upon IFN-β therapy (48). In the
present analysis, the type I IFN genes found to be regulated have
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Fig. 2. Influence of sun-exposure measures on clinical severity. (A) Map of
1-y averaged and erythemically weighted radiation reaching the earth’s
surface for Germany and France for the year 2015. White dots represent the
locations of the medical centers that contributed participants to either the
NationMS (only Germany) or the BIONAT (only France) cohort. (B) Dotplots
for MSSS in relation to 25(OH)D3 levels and latitude (of the patients’ medical
center) with least-squares linear regression lines ± SE for NationMS (nvitD =
761, nlat = 908). (C) Dotplot for Gd-enhancing lesions in relation to 25(OH)D3
levels (n = 761) and latitude (n = 908) for the NationMS cohort. Left y axis
corresponds to the dotplot displaying observed counts; right y axis corresponds
to the red line displaying mean number of lesions ± SE. (D) Dotplot for MSSS in
relation to 25(OH)D2+3 with least-squares linear regression line ± SE for BIONAT.
(E) Dotplots for MSSS in relation to latitude stratified by previous treatment
(nIFN-β=363, nNaive/GA = 248) with least-squares regression line ± SE. Analyses
for NationMS are adjusted for age, sex, BMI, smoking, alcohol consumption,
clinical subtype, neurological site of first manifestation, month of assessment,
and center. Analyses for BIONAT are adjusted for age, sex, neurological site of
first manifestation, month of assessment, and center. Adjustment for center was
omitted when analyzing the effect of latitude.
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previously been identified to be regulated upon IFN-β therapy in
RRMS patients who were classified as IFN-β therapy responders (49,
50). The down-regulation of AHR and TIPARP, known counter-
actors of type I IFN-signaling, further supports a direct up-
regulation of type I IFNs through phototherapy (51). Mechanisti-
cally, it is possible that the type I IFN expression is modulated by
vitD, as interactions between vitD and IFN-α/β have been described
previously (28, 29, 52). This is also in line with reports showing that
vitD and IFN-β–triggered gene expression partly overlaps (53).
Moreover, studies have proposed that UVR could also induce
type I IFNs via nucleic acid-damage and induction of damage-
associated molecular patterns that can be sensed by Toll-like
receptors and the stimulator of IFN genes (54, 55). Interest-
ingly, type I IFNs were also shown to be induced in the skin of
healthy human individuals upon UVR exposure, which is in lines
with the results from this study (56). If the type I IFN pathway
was indeed regulated by UVR, this could provide a link between
MS and lupus. In direct contrast to MS, in lupus, an autoimmune
disease that can manifest locally (e.g., cutaneous lupus eryth-
ematosus) or systemically (systemic lupus erythematosus), exposure
to UVR is known to be disease-worsening (57). Furthermore, lupus is
known to be partly driven by type I IFNs and patients often show an
increased type I IFN blood signature (58). Blockade of the type I IFN
pathway has been demonstrated to reduce disease severity in systemic
lupus erythematosus (59). In contrast, MS is associated with a re-
duced type I IFN signature and patients respond positively to IFN-β
therapy (28).
Furthermore, although sun exposure seems to be beneficial for
MS patients, it is also important to consider individual patient
characteristics, such as skin type and photosensitivity, and we
therefore also investigated modulatory effects of photosensitivity-
associated MC1R variants. In line with the concept of weak and
strong MC1R variant alleles (32), only the high-penetrance variant
rs1805008(C>T) showed a significant effect on self-reported skin
reaction to sun exposure, whereas no association was found for
rs885479(G>A) and rs2228479(G>A). The inverted effect of latitude
on the number of Gd-enhancing lesions in carriers and noncarriers of
the rs1805008 variant is in line with the observation of increased
photosensitivity and a higher grade of inflammation induced through
sun exposure, combined with the reduced responsiveness to antiin-
flammatory stimuli of α-melanocyte–stimulating hormone in carriers
of MC1R variant alleles (60, 61). The result should not be con-
founded by the major MS risk allele HLA-DRB1*15:01, since
rs1805008 has been shown not to be in linkage disequilibrium
with rs3135005, a nearly perfect proxy for HLA-DRB1*15:01
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Fig. 3. Influence of vitD and latitude on risk for relapses and disability accumulation. (A) Time-to-event curves displaying the proportion of relapse-free
patients over time for the NationMS cohort grouped by serum 25(OH)D3 levels (color code: jade = the 20% of patients with the lowest 25(OH)D3 levels,
cutpoint: <10.086 ng/mL; black = the 20% of patients with the highest 25(OH)D3 levels, cutpoint: ≥30.31 ng/mL; orange = patients in between) and com-
plemented with a table displaying the number at risk over time (n = 715). (B) Dotplot for the change in EDSS (ΔEDSS) in relation to baseline 25(OH)D3 levels
with least-squares linear regression line ± SE (n = 612). (C) Time-to-event curves displaying the proportion of relapse-free patients over time for the NationMS
cohort grouped by latitude (north defined as greater than or equal to median latitude within the cohort = 50.85 °N) and complemented with a table dis-
playing the number at risk over time (n = 798). (D) Dotplot for the ΔEDSS in relation to latitude with least-squares regression line ± SE (n = 671). Analyses are
adjusted for age, sex, BMI, smoking, alcohol consumption, clinical subtype, neurological site of first manifestation, month of assessment, medication after
baseline, whether medication was changed during the study, and center variability. Differences in baseline severity were adjusted by using the baseline MSSS
and the number of Gd-enhancing lesions at baseline as covariates. Adjustment for center was omitted when analyzing the effect of latitude.
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read-outs could be due to the fact that there was no evidence for
correlation between the MSSS and the number of Gd-enhancing
lesions. Weak or missing correlation between MRI activity and dis-
ability has been described previously, especially for early disease
forms (63). Furthermore, as the effects of MC1R in this study were
only nominally significant, the results must be interpreted with care
and require confirmation in larger cohorts.
Limitations of the study were that no information regarding
recent holidays abroad (e.g., in areas with very high or very low
sun exposure), no information regarding individual clothing be-
havior, and no information regarding the use of sunscreen was
available. However, as there was a strong correlation between
sampling de-seasonalized serum vitD and latitude in both
cohorts, no major bias seems to have been introduced by these
factors.
In summary, this study provides evidence for an effect of UVR
on severity and disease worsening in established MS. Although
excessive sun exposure is not recommended due the risk of skin
cancer, this argues for beneficial effects of moderate sun expo-
sure in MS. Mechanistically, vitD is supported as one of the main
mediators of UVR-effects, but a role for the type I IFN and the
MC1R pathway is brought up, as well. Differential effects of
UVR in carriers and noncarriers of MC1R variants were ob-
served, suggesting detrimental effects of UVR in sun-sensitive
patients. Previous therapy with IFN-β reduced the effect of lat-
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OR = 1.915 P = 0.038 OR = 2.050 P = 0.153 OR = 0.973 P = 0.936
rs1805008*Latitude interaction-P = 0.551 
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Fig. 4. Interaction of MC1R genotype and sun exposure. (A–C) Barplots displaying the fraction of total patients (ntotal = 229) who reported their reactions to
sun exposure at noon in summer for the MC1R genotypes (A) rs1805008(C>T), (B) rs885479(G>A), and (C) rs2228479(G>A). This analysis was adjusted for age,
sex, BMI, smoking, alcohol consumption, and population stratification. (D) Dotplots for MSSS in relation to latitude with least-squares linear regression line
stratified by rs1805008 genotype. (E) Dotplots for Gd-enhancing lesions in relation to latitude (left y axis) complemented with the mean number of lesions
(black line, right y axis). Analyses for D and E were adjusted for age, sex, BMI, smoking, alcohol consumption, clinical subtype, neurological site of first
manifestation, month of assessment, and center. Adjustment for center was omitted when analyzing the effect of latitude.
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Gene log2FC % regulation 
1. IFITM1 0.644 +56.262
2. IFIT2 0.494 +40.834
3. MX1 0.483 +39.765
4. IFITM3 0.326 +25.353
5. NR4A2 -0.570 -32.638
6. JAK1 -0.760 -40.950
7. AhR -0.851 -44.560
Gene log2FC % regulation 
1. IRF8 1.125 +118.015
2. VDR 0.461 +37.650
3. NR4A2 -0.427 -25.619
4. JAK1 -0.503 -29.436
Gene log2FC % regulation 
1. IRF7 0.795 +73.51
2. IFITM3 0.639 +55.725
3. IFIH1 0.466 +38.127
4. TNFAIP3 -0.468 -27.703
5. NR4A2 -0.598 -33.933
Gene log2FC % regulation 
1. IFITM1 0.617 +53.337
2. IFITM3 0.604 +51.993
3. IFI44L 0.576 +49.071
4. NFKBIA -0.299 -18.718
5. CDKN1A -0.570 -32.638
directly-/indirectly associated with vitD-signaling
directly-/indirectly associated with type I interferon-signaling
Fig. 5. Transcriptional effects of UVB-phototherapy in immune cells. (A) MS patients had been treated with UVB-phototherapy during the course of our 2014
pilot study (18). PBMC samples of five patients before and 6 wk after phototherapy (10 samples in total) have been used to isolate CD4+ T cells, CD8+ T cells,
B cells, and monocytes, that were then subjected to RNA-isolation and RNA-seq with subsequent bioinformatics analyses, including differential expression
analysis and gene set enrichment analysis (overrepresentation analysis). (B–E) Labeled, volcano plots for CD4+ T cells, CD8+ T cells, monocytes, and B cells. (F–I)
Before and after plots for exemplary genes associated with either the vitD or the type I IFN pathway, regulated by phototherapy in respective cell types. (J–M)
Venn diagrams for the overlap between significantly regulated genes in the respective cell types and the vitD and type I IFN gene sets (extracted from
wikipathways). P values were calculated from distribution-free permutation tests. The numbers for the reference gene sets refer to the number of genes
belonging to the reference gene set and that have detectable expression in the respective cell type.
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between latitude and vitD levels. This suggests that the effect of
latitude is at least in part mediated through vitD. This is also
complemented by the up-regulation of the vitD and the type I
IFN pathway in immune cells of UVB-treated MS patients,
which suggests involvement of both pathways in the mediation of
UVR-effects.
Methods
Patients. Data from the NationMS cohort, a prospective multicenter obser-
vational study, were used. In total, clinical data of 946 CIS/RRMS patients
recruited between 2010 and 2017 in 21 centers in Germany, were obtained
(64). Patients were followed-up and longitudinal data are available for 798
patients (Fig. 1). Included were patients with age ≥ 18 y, who were diag-
nosed with either CIS with fulfillment of three Barkhof criteria or confirmed
RRMS according to revised 2005 McDonald criteria. All patients were
treatment-naïve at baseline with onset of symptoms no longer than 2 y
before inclusion. The study was approved by the lead ethics committee
(Ethik-Kommission der Ruhr-Universität Bochum, registration no. 3714-10)
and all local committees. Informed written consent was obtained from all
participants and the study was performed according to the Declaration of
Helsinki. For replication, data of 990 patients from the BIONAT cohort (Study
identifier: NCT00942214), a French, multicenter cohort, at their baseline
assessment, were acquired (65). BIONAT patients were not treatment-naïve
before inclusion. Study investigators for NationMS and BIONAT can be
found in SI Appendix. For RNA-seq, PBMC of five patients from our 2014
pilot study were used (18).
Genotyping and Estimation of Population Stratification. Genotyping and QC
wer performed as previously published (66, 67). Briefly, genotyping was
performed using an Illumina OmniExpress chip and QC was performed in
PLINK v1.90. Genotypes for the most common MC1R variants were extracted
(rs1805008:C>T, rs885479:G>A, rs2228479:G>A), and population stratification was
calculated by multidimensional scaling as previously published (66).
Serum vitD Measurements. For NationMS, vitD was measured as the serum
level of 25(OH)D3. Measurement was performed in NationMS for n = 761
patients with a commercially available kit for liquid chromatography-mass
spectrometry (LC-MS/MS) (Recipe) on a Shimadzu 8040 LC–MS/MS instru-
ment coupled to a UHPLC system (Nexera, Shimadzu). For BIONAT, total
25(OH)D2+3 measurements were available for 579 patients. Total vitD has
been measured using a commercially available electro-chemiluminescence
competitive 25-hydroxyvitamin D binding assay (Cobas, Roche), and quan-
tified on a Roche Cobas 8000 e602 analyzer (Roche Diagnostics). As food-
derived vitD2 only contributes little to total serum vitD levels, there are only
minimal differences between total vitD and vitD3 serum levels.
Questionnaire on Photosensitivity. Of the NationMS cohort, 229 patients were
asked to report their skins potential reaction to sunlight at noon for 1 h
without the use of sunscreen in summer. Possible answers were “tan,”
“sunburn with a delayed tan,” “sunburn without tan and without blisters,”
and “sunburn without tan and with blisters.” Patients were asked to report
skin reddening, a feeling of heat and itching after 12 to 24 h as a sunburn,
and liquid-filled skin alterations with a diameter ≥5 mm as blisters. The
resulting variable was treated as ordinal.
Statistical Analysis. Disease severity outcomes were the MSSS and the number
of Gd-enhancing lesions (baseline). For longitudinal analyses, the increase/
decrease in EDSS 2 y after baseline and the time to relapse were assessed.
Explanatory variables were the two measures of UVR-exposure vitD and
latitude. For further confirmation, satellite data from NASA’s ozone moni-
toring instrument-dataset were used to generate coordinate- and time-
specific estimates of UVR exposure for each patient (methodology and re-
sults are reported in the SI Appendix, Supplementary Methods and Table S3).
The MSSS was modeled as a continuous variable and the influence of the
UVR-exposure measures was assessed using linear models. In the NationMS
cohort these analyses were adjusted for age, sex, body mass index (BMI =
weight/height2), smoking (yes/no), alcohol (yes/no), month of assessment
(treated as a categorical variable with 12 factor-levels), clinical subtype (CIS
or RRMS), and the site/symptom of first disease manifestation (coded as
categorical) (SI Appendix, Table S4). A random intercept was used to adjust
for center variability, which was omitted when assessing the influence of
latitude (latitude is intrinsic to the variability between centers and inclusion
would lead to unresolvable multicollinearity). For the BIONAT cohort, these
analyses were adjusted for age, sex, month of assessment, site/symptom of
first manifestation, and prior medication (other covariates not available for
BIONAT). Center variability was treated as in the NationMS cohort. For
BIONAT, the interaction of vitD or latitude and prior treatment was tested as
well, followed by subgroup analyses to obtain subgroup-specific estimates,
as some medications have been shown to modulate vitD synthesis (29).
The number of Gd-enhancing lesions in NationMS was modeled using a
zero-inflated negative binomial-model to account for overdispersion.
Confounder-adjustment was done as in the linear model. Plots for Gd-
enhancing lesions include a left y axis, showing the observed number of
lesions, and a right y axis, showing the mean number of lesions over x. The
influence of the MC1R genotype on skin reaction to sun exposure was
modeled using cumulative link models (ordinal regression) and adjusted for
age, sex, BMI, alcohol consumption, smoking, and population stratification
(first three multidimensional scaling components). To assess whether MC1R
genotype modifies the effect of UVR exposure on severity, an interaction
term between MC1R genotype and measures of sun exposure (latitude or
vitD) was added to the models for disease severity and adjusted as the prior
models for disease severity plus population stratification. To assess the in-
fluence of vitD and latitude on the risk for relapses in the NationMS cohort,
(mixed effects) Cox-regression was performed and adjusted as the baseline
models for disease severity plus initial medication after baseline (therapy
was initiated after baseline visit) and for whether medication was changed
during the course of the study. Medications were treated as substance
groups (e.g., IFN-β containing formulations from different suppliers were
grouped as one IFN-β group). The difference between the EDSS 2 y after
baseline and the baseline EDSS was calculated and declared as ΔEDSS. The
ΔEDSS was modeled using linear and linear mixed models and adjusted as
the baseline model plus the type of medication initiated after baseline
visit and whether medication was changed during the study. Additionally,
the models were adjusted for the number of lesions and the MSSS at
baseline to account for differences in baseline severity and disease dura-
tion. Model fit was assessed by inspection of scaled quantile residuals (68).
Model coefficients, Cis, and P values were reported from fully adjusted
models with significance threshold of α = 0.05 using two-sided tests. Genetic
analyses of the MC1R genotype that were not of confirmatory nature
(i.e., assessing disease severity and not skin reaction) were assessed for
genome-wide significance (α = 5 × 10−8).
UVB Phototherapy. Patient samples from a previous study were used where
patients had been irradiated with narrow-band UVB (311 nm). Irradiation
had been performed in a chamber for phototherapy equipped with Philips
TL-01 lamps (PDT 1200; Waldmann) for 6 wk (five sessions per week). In-
dividual minimal erythema doses were determined and 60% of minimal
erythema dose was used as the starting point. Per session, the dose was
then increased by 100 mJ/cm2 until either the maximum dose (900 mJ/cm2)
was reached or erythema occurred. A detailed description can be found in
the original study (18).
RNA-Seq Analysis. RNA-seq was performed using samples of five patients
from our 2014 pilot study (18). PBMC samples were sorted for CD4 T cells,
CD8 T cells, B cells, and monocytes. Samples were then prepared for se-
quencing using reagents from New England Biolabs and sequenced on an
Illumina NextSeq. 500 machine. Bioinformatic analysis was done in R using
Kallisto and edgeR. Results from Kallisto quantification can be found in
Datasets S7–10. Pathway analysis was performed using reference gene sets
fromwikipathways for permutation tests. A detailed description of the RNA-
seq workflow can be found in SI Appendix, SI Supplementary Methods.
Software. Statistical analyses were conducted in R v3.6.0 using the packages
stats, lme4, glmmTMB, ordinal, and DHARMa. To extract and process data
from NASA’s ozone monitoring instrument dataset, the package RNetCDF
was used. The remaining data were manipulated and plotted using the R
packages tidyR, ggplot2, and RColorBrewer. For population stratification
estimation, PLINK v1.90b5.2 was used. For analysis of RNA-seq data, Kallisto
and edgeR were used. For pathway extraction from wikipathways, the
package rWikiPathways was used.
Data Availability. Data and R code is available from the authors upon rea-
sonable request. Full results from RNA-seq can be found in Datasets S1–S10.
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